Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika inc. (T.ISA) -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (17)	6/27/2002 10:24:44 AM
From: teevee	Respond to of 23

Wednesday June 26, 7:46 am Eastern Time Roche Sees Cellcept Growing Around 20% In 2002 BASEL -(Dow Jones)- Swiss pharmaceutical company Roche Holding AG (RHHBY) said Wednesday that it expects its transplantation drug Cellcept to become one of its top-three products, with sales of around CHF1.4 billion in 2003. Roche also said it expects sales of Cellcept to rise around 20% this year. These estimates take into account the expected launch of a rival products from Novartis AG (Z.NOV), Roche said. The company provided its estimate at a media conference on its transplantion drugs franchise. Sales of Cellcept rose 34% to CHF1.06 billion in 2001. Over 60% of kidney and 40% of heart transplant patients are treated with Cellcept, Roche said. Company Web site: roche.com Roche also said it has a 25% share of the global transplantation market. It sees sales of its transplantation portfolio rising to more than CHF2 billion in 2007 and to more than CHF3 billion in 10 years from CHF1.32 billion in 2001. Of the company's other drugs in its transplantation portfolio, Roche said it expects that Zenapax has potential sales of CHF100 million and it sees its Cymevene-Walcyte franchise with sales of CHF550 million by 2007. The company also said it expects a transplantation drug in phase two clinical development, ISA247, to be launched in some five years. The company expects the drug, which is being codeveloped with Isotechnika, to have a market potential of more than CHF1 billion in annual sales.